Cargando…

Osteoporosis – a current view of pharmacological prevention and treatment

Postmenopausal osteoporosis is the most common bone disease, associated with low bone mineral density (BMD) and pathological fractures which lead to significant morbidity. It is defined clinically by a BMD of 2.5 standard deviations or more below the young female adult mean (T-score =−2.5). Osteopor...

Descripción completa

Detalles Bibliográficos
Autores principales: Das, Subhajit, Crockett, Julie C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686324/
https://www.ncbi.nlm.nih.gov/pubmed/23807838
http://dx.doi.org/10.2147/DDDT.S31504
_version_ 1782273787118485504
author Das, Subhajit
Crockett, Julie C
author_facet Das, Subhajit
Crockett, Julie C
author_sort Das, Subhajit
collection PubMed
description Postmenopausal osteoporosis is the most common bone disease, associated with low bone mineral density (BMD) and pathological fractures which lead to significant morbidity. It is defined clinically by a BMD of 2.5 standard deviations or more below the young female adult mean (T-score =−2.5). Osteoporosis was a huge global problem both socially and economically – in the UK alone, in 2011 £6 million per day was spent on treatment and social care of the 230,000 osteoporotic fracture patients – and therefore viable preventative and therapeutic approaches are key to managing this problem within the aging population of today. One of the main issues surrounding the potential of osteoporosis management is diagnosing patients at risk before they develop a fracture. We discuss the current and future possibilities for identifying susceptible patients, from fracture risk assessment to shape modeling and in relation to the high heritability of osteoporosis now that a plethora of genes have been associated with low BMD and osteoporotic fracture. This review highlights the current therapeutics in clinical use (including bisphosphonates, anti-RANKL [receptor activator of NF-κB ligand], intermittent low dose parathyroid hormone, and strontium ranelate) and some of those in development (anti-sclerostin antibodies and cathepsin K inhibitors). By highlighting the intimate relationship between the activities of bone forming (osteoblasts) and bone-resorbing (osteoclasts) cells, we include an overview and comparison of the molecular mechanisms exploited in each therapy.
format Online
Article
Text
id pubmed-3686324
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-36863242013-06-27 Osteoporosis – a current view of pharmacological prevention and treatment Das, Subhajit Crockett, Julie C Drug Des Devel Ther Review Postmenopausal osteoporosis is the most common bone disease, associated with low bone mineral density (BMD) and pathological fractures which lead to significant morbidity. It is defined clinically by a BMD of 2.5 standard deviations or more below the young female adult mean (T-score =−2.5). Osteoporosis was a huge global problem both socially and economically – in the UK alone, in 2011 £6 million per day was spent on treatment and social care of the 230,000 osteoporotic fracture patients – and therefore viable preventative and therapeutic approaches are key to managing this problem within the aging population of today. One of the main issues surrounding the potential of osteoporosis management is diagnosing patients at risk before they develop a fracture. We discuss the current and future possibilities for identifying susceptible patients, from fracture risk assessment to shape modeling and in relation to the high heritability of osteoporosis now that a plethora of genes have been associated with low BMD and osteoporotic fracture. This review highlights the current therapeutics in clinical use (including bisphosphonates, anti-RANKL [receptor activator of NF-κB ligand], intermittent low dose parathyroid hormone, and strontium ranelate) and some of those in development (anti-sclerostin antibodies and cathepsin K inhibitors). By highlighting the intimate relationship between the activities of bone forming (osteoblasts) and bone-resorbing (osteoclasts) cells, we include an overview and comparison of the molecular mechanisms exploited in each therapy. Dove Medical Press 2013-05-31 /pmc/articles/PMC3686324/ /pubmed/23807838 http://dx.doi.org/10.2147/DDDT.S31504 Text en © 2013 Das and Crockett, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Das, Subhajit
Crockett, Julie C
Osteoporosis – a current view of pharmacological prevention and treatment
title Osteoporosis – a current view of pharmacological prevention and treatment
title_full Osteoporosis – a current view of pharmacological prevention and treatment
title_fullStr Osteoporosis – a current view of pharmacological prevention and treatment
title_full_unstemmed Osteoporosis – a current view of pharmacological prevention and treatment
title_short Osteoporosis – a current view of pharmacological prevention and treatment
title_sort osteoporosis – a current view of pharmacological prevention and treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686324/
https://www.ncbi.nlm.nih.gov/pubmed/23807838
http://dx.doi.org/10.2147/DDDT.S31504
work_keys_str_mv AT dassubhajit osteoporosisacurrentviewofpharmacologicalpreventionandtreatment
AT crockettjuliec osteoporosisacurrentviewofpharmacologicalpreventionandtreatment